• ARS Pharmaceuticals held its annual shareholder meeting on June 24, 2026.
• Shareholders backed the appointment of Ernst & Young LLP as independent auditor for the fiscal year ending Dec. 31, 2026.
• Investors also chose an annual schedule for future advisory votes on executive pay; the board determined it will hold those votes annually.
• Three directors were selected to serve as Class III directors through the 2029 annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-282994), on June 25, 2026, and is solely responsible for the information contained therein.